Search
CYTK/BMY: aficamten approvable, but may not be better than BMY rival Camzyos
While at first sight, the body of aficamten data in obstructive hypertrophic cardiomyopathy (oHCM) may appear slightly ahead of Camzyos on efficacy and safety, with no cases of low heart strength (LVEF) and so fewer dose interruptions, our detailed analysis reveals key differences in...
